Polygenic Liability for Major Psychiatric Disorders and Clinical Features of Schizophrenia

AI Summary

Higher bipolar disorder polygenic score predicted less PANSS improvement and earlier treatment discontinuation in European ancestry CATIE sample, independent of other scores.
Major depressive disorder and schizophrenia polygenic scores showed no baseline symptom associations; SCZ-PGS item associations in mixed sample reflected population stratification.
Effects are small, not clinically actionable; PGS-symptom findings from ancestrally mixed samples require replication within a single ancestry before clinical interpretation.

TL;DR (AI Generated)

Higher BD-PGS predicted less improvement in PANSS Total (β = 1.69 per SD, one-tailed p = 0.036, q = 0.036) and earlier treatment discontinuation (HR = 1.16, 95% CI 1.004-1.340, q = 0.036); joint models with all three scores did not account for either effect.

The four motor/behavioral item-level associations with SCZ-PGS detected in the ancestrally mixed sample (ρ = 0.11-0.14) did not survive European-only analysis, were not reproduced by removing 72 participants at random (permutation p ≤ 0.002), and reflect a score that differs by 1.5 SD between ancestry groups: population stratification.

Basic summary

Am J Med Genet B Neuropsychiatr Genet. 2026 Oct 19. doi: 10.1002/ajmg.b.70039. Online ahead of print.

ABSTRACT

Polygenic scores (PGS) for schizophrenia (SCZ), major depressive disorder (MDD), and bipolar disorder (BD) are used to explain heterogeneity in schizophrenia, but European-derived scores applied in ancestrally mixed samples risk confounding by population structure. In the CATIE trial, we tested 3 a priori directional hypotheses under one rule: covariate-adjusted model, one-tailed p, within-family false-discovery-rate correction. The primary sample was 407 participants of European ancestry, with principal components recomputed within it; scores were computed with PRS-CS. Higher BD-PGS predicted less improvement in PANSS Total (β = 1.69 per SD, one-tailed p = 0.036, q = 0.036) and earlier treatment discontinuation (HR = 1.16, 95% CI 1.004-1.340, q = 0.036); joint models with all three scores did not account for either effect. MDD-PGS and SCZ-PGS were unassociated with baseline symptoms. The four motor/behavioral item-level associations with SCZ-PGS detected in the ancestrally mixed sample (ρ = 0.11-0.14) did not survive European-only analysis, were not reproduced by removing 72 participants at random (permutation p ≤ 0.002), and reflect a score that differs by 1.5 SD between ancestry groups: population stratification. Effects are small and not clinically actionable; PGS-symptom associations from mixed samples should be treated as provisional until replicated within one ancestry.

PMID:42894926 | DOI:10.1002/ajmg.b.70039

Document this CPD